Otros idiomas Amgen Inc. Sao Paulo

Acciones

AMGN34

BRAMGNBDR004

Mercado cerrado - Sao Paulo Otros sitios de cotización 18:42:47 21/06/2024			Varia. Cinco días.	Varia. 1 de enero.
60,36 ^BRL	+0,43 %		+5,49 %	+20,84 %

21/06	La FDA estadounidense aprueba un fármaco de Roche para un trastorno sanguíneo crónico	RE
14/06	Amgen Inc. anuncia que la Administración de Alimentos y Medicamentos de EE.UU. aprueba Blincyto	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

US FDA approves Roche's drug for a chronic blood disorder	21/06
Amgen : Bringing Cardiovascular Care to the Heart of Communities	20/06
Amgen : Continues to Propel BiTE® Technology Innovation	20/06
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	14/06
Amgen : Continues to Propel BiTE® Technology Innovation	14/06
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	14/06
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	14/06
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	14/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500	13/06
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06/06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	05/06
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	05/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Amgen Inc. Sao Paulo

Acciones

AMGN34

BRAMGNBDR004

Otros idiomas

Filtros